Skip to main content

Table 1 Demographic and clinical data

From: The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old

 

no-ATT

PI

VKA

DOAC

p value

n

80

41

32

33

 

Age

74 (64.5–81)

80 (72–86)

81 (74–85)

82 (75.5–84.5)

< 0.0001

Male gender (n/%)

48 (60%)

21 (51.2%)

15 (46.9%)

14 (42.4%)

ns

GCS

14 (12–15)

14.5 (12.75–15)

14 (13–15)

14 (14–15)

ns

AIS Head

3 (2–4)

3 (3–4)

3 (3–4.75)

3 (2.25–4)

ns

ISS

13 (9–17)

14.5 (9–18)

14.5 (9.25–23.75)

10 (9–16)

ns

Charlson Comorbidity Index

3 (2–5)

4 (3.5–5)

4 (4–6)

5 (4–6)

0.0006

Number of CCT

3 (2–5)

3 (3–5)

3.5 (2–6)

3 (2–5)

ns

ICH progression (n/%)

27 (33.7)

16 (39.0)

19 (59.4)

8 (24.2)

0.023

ICU length of stay

46 (21.25–112.3)

47 (25–108)

70 (29.25–159.5)

49 (22–92)

ns

Hospital length of stay

242 (123–407.5)

217 (121–413)

278.5 (109.5–368)

168 (76–345.5)

ns

  1. no-ATT no antithrombotic therapy, PI platelet inhibitors, VKA vitamin K antagonists, DOAC direct oral anticoagulants, GCS Glasgow coma scale, AIS abbreviated injury score, ISS injury severity score, CCT cranial computer tomography, ICH intracranial haematoma, ICU intensive care unit, ns not significant
  2. ANOVA and Dunnett’s comparison of all columns vs. control column
  3. Chi square test
  4. Median (interquartile range, 25th–75th)